Primary AEGEAN Analysis Shows Improved EFS, pCR with Periadjuvant Durvalumab

Air Pollution and Lung Cancer: A Q&A with Professor Charles Swanton

ADAURA Demonstrates OS Benefit with Adjuvant Osimertinib in Resectable EGFRm NSCLC

Data Supporting IO Before Surgery in Resectable NSCLC Grows

From the Editors: Defining Resectability of Non-Small Cell Lung Cancer in 2023

Tumor Treating Fields May Provide Additional Treatment Option for mNSCLC Following Progression

From the Editors: Those in Thoracic Oncology Field Must Educate Themselves About Artificial Intelligence

International Group Consensus Statement Offers Technical Guidance for MPM Imaging

Demystifying AI: Current Insights on Artificial Intelligence in Thoracic Oncology

Artificial Intelligence in Healthcare: A Patient Perspective

Neoadjuvant Immunotherapy in NSCLC: A Window of Opportunity Not to Be Missed

Adjuvant IO for Operable NSCLC: Where Does It Fit a Changing Landscape?